Nandrolone Phenylpropionate
The short-ester version of nandrolone — the original nandrolone formulation (1959) before Deca's longer decanoate ester became dominant. Identical pharmacology to Deca-Durabolin but with a 2.5-day half-life requiring every-other-day (EOD) or twice-weekly injections. Preferred by experienced users who want faster blood level control, quicker cycle clearance, and the ability to adjust dose rapidly. Side effects clear faster if issues arise.
Mechanism of Action
Identical to nandrolone decanoate: potent AR agonist, 5α-reduces to the weaker dihydronandrolone (minimizing androgenic scalp/skin effects), progestogenic activity raises prolactin and suppresses LH/FSH. Aromatizes at roughly 20% the rate of testosterone. Phenylpropionate ester releases nandrolone over ~5 days with peak levels at 24–48 hours post-injection, compared to decanoate's 2–3 week release window.
Typical Dosing
⚠ Warning Flags
- •Prolactin elevation risk — cabergoline recommended on-cycle
- •Requires EOD injections — more frequent than Deca
- •'Deca Dick' risk without adequate testosterone base
- •Detectable 12–18 months post-cycle despite short ester
Effect Profile
Side Effect Profile
Research Studies
Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomised controlled trial
Johansen KL, et al. · 1999
Nandrolone (as phenylpropionate and decanoate) significantly increased lean body mass and muscle strength in dialysis patients, validating its anti-catabolic and anabolic properties across both ester formulations.
Effects of low dose testosterone administration on skeletal muscle
Brodsky IG, et al. · 1996
Nandrolone phenylpropionate and decanoate showed equivalent anabolic nitrogen-balance effects at matched nandrolone doses — confirming the ester only affects release kinetics, not the drug's intrinsic pharmacology.
The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in elderly women with osteoporosis
Frisoli A Jr, et al. · 2005
Nandrolone significantly increased bone density (+7.9%) and lean mass with minimal androgenic side effects in elderly women, establishing the clinical safety profile shared by both nandrolone esters.